However, previous study showed that NU7441 could induce resistance to PARP inhibitor in BRCA1-defective cells (McCormick et al., 2017), and BMS-754807 combined with carboplatin/paclitaxel was observed resistance in ovarian carcinosarcoma of patient-derived xenograft (Glaser et al., 2015). Here, BRCA1 is linked to ovarian carcinosarcoma.